Table of Contents

company-logo

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.

Kintor Pharmaceutical Dividend Announcement

• Kintor Pharmaceutical does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Kintor Pharmaceutical dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Kintor Pharmaceutical Dividend History

Kintor Pharmaceutical Dividend Yield

Kintor Pharmaceutical current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kintor Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:

Kintor Pharmaceutical Financial Ratios

P/E ratio-0.47
PEG ratio-0.00
P/B ratio0.00
ROE-0.46%
Payout ratio0.00%
Current ratio2.10
Quick ratio2.10
Cash Ratio1.98

Kintor Pharmaceutical Dividend FAQ

Does Kintor Pharmaceutical stock pay dividends?
Kintor Pharmaceutical does not currently pay dividends to its shareholders.
Has Kintor Pharmaceutical ever paid a dividend?
No, Kintor Pharmaceutical has no a history of paying dividends to its shareholders. Kintor Pharmaceutical is not known for its dividend payments.
Why doesn't Kintor Pharmaceutical pay dividends?
There are several potential reasons why Kintor Pharmaceutical would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Kintor Pharmaceutical ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Kintor Pharmaceutical has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Kintor Pharmaceutical a dividend aristocrat?
Kintor Pharmaceutical is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Kintor Pharmaceutical a dividend king?
Kintor Pharmaceutical is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Kintor Pharmaceutical a dividend stock?
No, Kintor Pharmaceutical is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Kintor Pharmaceutical stocks?
To buy Kintor Pharmaceutical you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Kintor Pharmaceutical stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.